Dr. Paul Swiecicki
Claim this profileUniversity of Michigan Comprehensive Cancer Center
Expert in Cancer
Studies Squamous Cell Carcinoma
19 reported clinical trials
29 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
metastatic
2Squamous Cell Carcinoma
Stage IV
metastatic
Stage III
Affiliated Hospitals
Clinical Trials Paul Swiecicki is currently running
Trastuzumab Emtansine
for Salivary Gland Cancer
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab emtansine may work better compared to usual treatment of chemotherapy with docetaxel and trastuzumab in treating patients with salivary gland cancer.
Recruiting1 award Phase 2
Cyclophosphamide + Sirolimus
for Advanced Thyroid Cancer
This trial uses two drugs, Cyclophosphamide and Sirolimus, to treat patients with thyroid cancer that has spread. Cyclophosphamide kills cancer cells by breaking their DNA, while Sirolimus stops them from growing. Sirolimus has been used in various treatments and has shown effectiveness against different cancers. Patients are monitored for side effects and effectiveness.
Recruiting1 award Phase 211 criteria
More about Paul Swiecicki
Clinical Trial Related1 year of experience running clinical trials · Led 19 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Paul Swiecicki has experience with
- Pembrolizumab
- Carboplatin
- Docetaxel
- Cisplatin
- Intensity-Modulated Radiation Therapy
- KVA12123 Treatment
Breakdown of trials Paul Swiecicki has run
Cancer
Squamous Cell Carcinoma
Melanoma
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paul Swiecicki specialize in?
Paul Swiecicki focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Paul Swiecicki currently recruiting for clinical trials?
Yes, Paul Swiecicki is currently recruiting for 10 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Paul Swiecicki has studied deeply?
Yes, Paul Swiecicki has studied treatments such as Pembrolizumab, Carboplatin, Docetaxel.
What is the best way to schedule an appointment with Paul Swiecicki?
Apply for one of the trials that Paul Swiecicki is conducting.
What is the office address of Paul Swiecicki?
The office of Paul Swiecicki is located at: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.